GlaxoSmithKline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Ltd

Health CarePharmaceuticals & Biotechnology
  • Price (INR)1,495.20
  • Today's Change5.80 / 0.39%
  • Shares traded64.97k
  • 1 Year change-5.00%
  • Beta0.5696
Data delayed at least 15 minutes, as of Sep 28 2021 11:24 BST.
More ▼
Take Survey
Help shape our future virtual events & community services
Take part in our survey for a chance to win a free 3-month standard gift subscription.

Profile data is unavailable for this security.

About the company

GlaxoSmithKline Pharmaceuticals Limited is a pharmaceutical company. The Company and its subsidiary are engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in approximately three areas, including pharmaceuticals, vaccines and consumer healthcare. The Company's product portfolio includes prescription medicines and vaccines. The Company's prescription medicines range across therapeutic areas, and it also offers a range of vaccines for prevention of life-threatening diseases, such as pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough, small pox and influenza. It provides healthcare solutions to patients, with a range of prescription medicines across areas covering anti-infectives, dermatology, gynecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The Company's manufacturing unit is located at Nashik, and its clinical development center is located in Bangalore.

  • Revenue in INR (TTM)33.40bn
  • Net income in INR3.68bn
  • Incorporated1924
  • Employees4.28k
  • Location
    GlaxoSmithKline Pharmaceuticals LtdDr Annie Besant Road, WorliMUMBAI 400030IndiaIND
  • Phone+91 2 224959595
  • Fax+91 2 224981526
  • Websitehttp://india-pharma.gsk.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Suven Pharmaceuticals Ltd10.35bn3.76bn134.96bn1.11k35.91--32.9613.0414.7614.7640.66--------9,293,424.00--------55.89--36.31----------21.10--14.30------
Glenmark Pharmaceuticals Ltd115.64bn10.23bn142.10bn13.39k13.90--9.691.2336.2436.24409.83--------8,636,323.00--6.56--9.0565.1661.728.848.77--5.18--7.652.857.4325.026.68-2.744.56
J B Chemicals and Pharmaceuticals Ltd21.26bn4.47bn144.49bn4.12k32.30--27.936.8057.8957.89275.08--------5,158,237.00--13.74--16.5365.5858.6421.0715.01--112.61--24.8915.0910.9265.7022.48-25.1426.97
Alembic Pharmaceuticals Ltd53.78bn10.41bn154.94bn12.16k14.68--13.292.8853.6953.69276.41--------4,422,574.00--15.19--20.9175.7467.3118.0416.51--103.93--19.4217.1011.2442.1410.3516.9828.47
Natco Pharma Ltd.18.99bn3.93bn159.94bn5.05k40.73--30.888.4221.5421.54104.03--------3,763,377.00--14.94--18.0878.3375.3320.8226.36--36.40--22.177.1613.70-4.3223.2710.1033.24
Sanofi India Ltd29.21bn5.80bn182.93bn2.91k31.5311.4027.616.26251.89251.891,268.38697.030.97793.5823.6810,031,250.0019.4213.3925.8717.0056.7656.7019.8613.931.41419.530.0164113.43-5.495.7615.3114.98-23.5223.79
Ajanta Pharma Ltd29.69bn6.80bn188.71bn7.04k27.86--23.626.3578.2878.28341.87--------4,221,009.00--19.19--22.7677.6576.3222.8921.29--107.56----11.6610.5639.819.49-10.453.50
Syngene International Ltd23.57bn4.24bn252.17bn5.40k60.22--35.6510.7010.5410.5458.51--------4,365,185.00--9.98--13.8673.2171.2018.0020.14--------8.5714.56-1.7510.958.67--
GlaxoSmithKline Pharmaceuticals Limited33.40bn3.68bn252.31bn4.28k68.49--56.887.5521.7521.75197.12--------7,798,885.00--9.37--14.1459.1252.5411.0310.37--202.90--129.61-0.79142.42225.22-0.9755-28.233.71
IPCA Laboratories Ltd54.51bn10.01bn300.91bn14.57k30.02--24.745.5279.0279.02430.33--------3,740,483.00--11.50--15.1266.2059.6718.3812.93--67.44--9.5716.5813.2888.0265.037.91--
Laurus Labs Ltd51.18bn10.53bn321.80bn4.49k30.69--25.376.2919.5419.5494.97--------11,392,900.00--10.11--17.7755.7246.6920.5912.14--18.55--6.0069.9921.59285.3149.0416.08--
Data as of Sep 28 2021. Currency figures normalised to GlaxoSmithKline Pharmaceuticals Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

11.00%Per cent of shares held by top holders
HolderShares% Held
Life Insurance Corp of Indiaas of 31 Mar 20218.09m4.78%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Aug 20215.86m3.46%
General Insurance Corp. of India (Invt Port)as of 31 Mar 20212.40m1.42%
The Vanguard Group, Inc.as of 03 Sep 20211.22m0.72%
ICICI Prudential Asset Management Co. Ltd.as of 31 Aug 2021440.11k0.26%
Norges Bank Investment Managementas of 31 Dec 2020272.39k0.16%
Dimensional Fund Advisors LPas of 02 Sep 2021121.18k0.07%
SBI Funds Management Pvt Ltd.as of 31 Aug 2021106.90k0.06%
Charles Schwab Investment Management, Inc.as of 01 Sep 202165.18k0.04%
Tata Asset Management Ltd.as of 31 Aug 202153.36k0.03%
More ▼
Data from 31 Dec 2020 - 21 Sep 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.